Takeda to Gain Selective PI3K and mTOR Inhibitors via Intellikine Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)
Published: 9 Jan-2012
DOI: 10.3833/pdr.v2012.i1.1653 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Via its US subsidiary Takeda America Holdings, Takeda Pharmaceutical has moved to strengthen its oncology pipeline by agreeing to acquire Intellikine for up to US$310 M, including US$190 M in cash upfront and up to US$120 M in potential clinical development milestone payments...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS